198 related articles for article (PubMed ID: 26550047)
1. Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.
Lee I; Paeng JC; Lee SJ; Shin CS; Jang JY; Cheon GJ; Lee DS; Chung JK; Kang KW
Nucl Med Mol Imaging; 2015 Dec; 49(4):284-90. PubMed ID: 26550047
[TBL] [Abstract][Full Text] [Related]
2. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
7. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
8. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
11.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
14. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
16. (68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.
Kroiss A; Shulkin BL; Uprimny C; Frech A; Gasser RW; Url C; Gautsch K; Madleitner R; Nilica B; Sprinzl GM; Gastl G; Fraedrich G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):33-41. PubMed ID: 25134670
[TBL] [Abstract][Full Text] [Related]
17. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies.
Lincke T; Singer J; Kluge R; Sabri O; Paschke R
Thyroid; 2009 Apr; 19(4):381-9. PubMed ID: 19355828
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
19. Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging.
Zhang-Yin J; Dirand AS; Sasanelli M; Corrégé G; Peudon A; Kiffel T; Nataf V; Clerc J; Montravers F; Talbot JN
J Nucl Med; 2017 Aug; 58(8):1230-1235. PubMed ID: 28209907
[No Abstract] [Full Text] [Related]
20. Detection of "Incidentalomas" on Brain and Body
Umana GE; Ferini G; Harikar MM; Venkataram T; Costanzo R; Scalia G; Palmisciano P; Brunasso L; Paolini F; Sciortino A; Maugeri R; Crea A; Barone F; Inserra F; DA Ros V; Cuttone G; Corsale G; Cristaudo C; Cosentino S; Sabini MG; Ippolito M
Anticancer Res; 2022 Dec; 42(12):5867-5873. PubMed ID: 36456146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
